In the persistence of the following diseases and conditions usage of combined oral contraceptives is contraindicated. In case of first appearance of the diseases as follows while taking combined contraceptive film-coated tablets, its application should be stopped immediately.
Usage of Dienille is contraindicated: hypersensitivity to any of the active ingredients and excipients of the film-coated tablet;
existing venous thrombosis (deep venous thrombosis, pulmonary embolism) or positive patient history;
existing arterial thrombosis (cerebrovascular event, heart attack) or positive patient history or even in the presence of prodromal events (such as angina pectoris, and transient ischemic attack);
in the presence of a severe risk factor or multiple risk factors of arterial thrombosis: diabetes mellitus with vascular involvement; severe hypertension; severe dyslipidaemia; biochemical factors that may be indicative of hereditary or acquired predisposition for venous or arterial thrombosis including activated protein C (APC) resistance, hyperhomocysteinaemia, antithrombin-III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant);
active severe liver disease or positive patient history for it, if liver function tests have not been normalized yet;
active liver tumor (benign or malignant) or a positive patient history for it;
known or suspected steroid-dependent tumors, (tumors of genital organs or breasts);
vaginal bleeding of unknown origin;
migraine with focal neurological symptoms in the patient history;
pancreatitis or a history thereof if associated with severe hypertriglyceridaemia;
severe renal insufficiency or acute renal failure.
Dienille is contraindicated for concomitant use with the medicinal products containing ombitasvir / paritaprevir / ritonavir and dasabuvir (See Precautions and Interactions).